CLINICAL GUIDELINES GENETIC TESTING

CURRENT GENETIC TESTING GUIDELINES

COMING SOON

AIM builds a new Genetic Testing solution by leveraging its market-leading guideline development process, clinical strengths, and provider transparency

New AIM Clinical Appropriateness Guidelines for Genetic Testing

The foundation of our solution platform for specialty benefits management is our clinical appropriateness guidelines.

AIM Clinical Appropriateness Guidelines for Genetic Testing are developed through a rigorous process integrating evidence-based literature with expert review. Included are guidelines for hereditary cancer testing, somatic tumor testing, cell-free DNA testing for management of cancer, prenatal testing using cell-free DNA, cancer screening in the prenatal setting and preimplantation testing, testing for inherited conditions, chromosomal microarray analysis, whole exome and whole genome sequencing, pharmacogenomic testing, and polygenic risk scores.

The Guidelines do not address coverage, benefit or other plan specific issues. Applicable federal and state coverage mandates take precedence over these clinical guidelines. If requested by a health plan, AIM will review requests based on health plan medical policy/guidelines in lieu of the AIM Guidelines.

AIM Clinical Appropriateness Guidelines for Hereditary Cancer Testing

The testing addressed in the new AIM Clinical Appropriateness Guidelines for Hereditary Cancer Testing includes screening for hereditary cancer predisposition syndromes.

COMING SOON NEW GUIDELINES FOR HEREDITARY CANCER TESTING EFFECTIVE FEBRUARY 12, 2023

AIM Clinical Appropriateness Guidelines for Somatic Tumor Testing

The testing addressed in the new AIM Clinical Appropriateness Guidelines for Somatic Tumor Testing includes genetic testing and gene expression profiling of solid and hematologic tumors for the purpose of diagnosis or for information related to treatment selection, prognosis, or recurrence risks.

COMING SOON NEW GUIDELINES FOR SOMATIC TUMOR TESTING EFFECTIVE FEBRUARY 12, 2023

AIM Clinical Appropriateness Guidelines for Cell-free DNA Testing for the Management of Cancer

The testing addressed in the new AIM Appropriateness Guidelines for Cell-free DNA for the Management of Cancer includes testing and screening for the detection of Circulating tumor DNA (ctDNA) for guiding tumor-specific treatment.

COMING SOON NEW GUIDELINES FOR CELL-FREE DNA TESTING FOR MANAGEMENT OF CANCER EFFECTIVE FEBRUARY 12, 2023

AIM Clinical Appropriateness Guidelines for Prenatal Testing using Cell-free DNA

The testing addressed in the new AIM Appropriateness Guidelines for Prenatal Testing using Cell-free DNA includes prenatal screening for aneuploidies in the fetus.

COMING SOON NEW GUIDELINES FOR PRENATAL TESTING USING CELL-FREE DNA EFFECTIVE FEBRUARY 12, 2023

AIM Clinical Appropriateness Guidelines for Cancer Screening in the Prenatal Setting and Preimplantation Testing

The testing addressed in the new AIM Appropriateness Guidelines for Carrier Screening in the Prenatal Setting and Preimplantation Genetic Testing includes carrier testing for familial mutations and common and ethnic genetic diseases as well as for preimplantation screening and diagnosis.

COMING SOON NEW GUIDELINES FOR CANCER SCREENING IN THE PRENATAL SETTING AND PREIMPLANTATION GENETIC TESTING EFFECTIVE FEBRUARY 12, 2023

AIM Clinical Appropriateness Guidelines for Genetic Testing for Inherited Conditions

The testing addressed in the new AIM Appropriateness Guidelines for Genetic Testing for Inherited Conditions includes single-gene testing, multigene diagnostic panels, and testing for variants associated with multifactorial conditions.

COMING SOON NEW GUIDELINES FOR GENETIC TESTING FOR INHERITED CONDITIONS EFFECTIVE FEBRUARY 12, 2023

AIM Clinical Appropriateness Guidelines for Chromosomal Microarray Analysis

The testing addressed in the new AIM Appropriateness Guidelines for Chromosomal Microarray Analysis includes cytogenetic microarray (CMA) platforms for the detection of DNA copy number gains and losses associated with unbalanced chromosomal aberrations in both prenatal and postnatal evaluations.

COMING SOON NEW GUIDELINES FOR CHROMOSOMAL MICROARRAY ANALYSIS EFFECTIVE FEBRUARY 12, 2023

AIM Clinical Appropriateness Guidelines for Whole Exome Sequencing and Whole Genome Sequencing

The testing addressed in the new AIM Appropriateness Guidelines for Whole Exome Sequencing and Whole Genome Sequencing includes the diagnostic use of whole exome and genome sequencing in the evaluation of rare disease.

COMING SOON NEW GUIDELINES FOR WHOLE EXOME AND WHOLE GENOME SEQUENCING EFFECTIVE FEBRUARY 12, 2023

AIM Clinical Appropriateness Guidelines for Pharmacogenomic Testing

The testing addressed in the new AIM Appropriateness Guidelines for Pharmacogenomic Testing includes genotype testing to predict response to certain medications and testing for gene mutations associated with coagulation disorders.

COMING SOON NEW GUIDELINES FOR PHARMACOGENOMIC TESTING EFFECTIVE FEBRUARY 12, 2023

AIM Clinical Appropriateness Guidelines for Polygenic Risk Scores

The testing addressed in the new AIM Appropriateness Guidelines for Polygenic Risk Scores includes testing and screening using the aggregation of common, low penetrance variants into a weighted risk score in order to calculate the inherited component of an individual’s lifetime risk of a disease.

COMING SOON NEW GUIDELINES FOR POLYGENIC RISK SCORES EFFECTIVE FEBRUARY 12, 2023

New Genetic Testing Guidelines developed by AIM Specialty Health. © 2022 AIM Specialty Health. All rights reserved.

AIM General Clinical Guideline

OPEN THE GENERAL CLINICAL GUIDELINE

 

 

Trouble viewing the guidelines?

To open our guidelines, your computer needs Adobe Reader, a free and trusted software that allows you to view PDFs.

GET ADOBE READER